ulcerative colitis

Unlocking the Sleeper Effect: Can Mechanism-Based Psychological Interventions Transform IBS and UC Outcomes?

By MedXY 12/29/2025

The SOMA.GUT-RCT investigated a targeted psychological intervention for IBS and UC. While the primary 3-month endpoint showed no significant symptom reduction compared to standard care, exploratory data revealed significant psychological improvements and a delayed clinical benefit at 12 months, highlighting the potential for integrated care.

Gastroenterology Internal Medicine news

Moving Beyond Injectables: SOR102 Shows Promise as an Oral Dual-Inhibitor for Ulcerative Colitis

By MedXY 12/20/2025

A Phase 1 trial of SOR102, a first-in-class oral bispecific antibody targeting TNF and IL-23, demonstrates favorable safety and preliminary clinical activity in patients with ulcerative colitis, suggesting a potential shift toward localized, dual-targeted oral biologics.

Gastroenterology news

Etrasimod Shows Robust Induction and Maintenance Efficacy in East Asian Patients with Moderate–Severe Ulcerative Colitis

By MedXY 11/09/2025

A phase 3 randomized trial in East Asia found oral etrasimod 2 mg superior to placebo for induction and maintenance of clinical remission in moderate–severe ulcerative colitis, with manageable safety and notable ALT elevations.

Gastroenterology Internal Medicine

Simplifying Ulcerative Colitis Treatment: Evaluating a Single 1600 mg 5-ASA Tablet Regimen in the EASI Trial

By MedXY 10/09/2025

The EASI trial compared a once-daily 1600 mg 5-ASA tablet with the conventional three 800 mg tablet regimen for ulcerative colitis, finding similar adherence and relapse rates, suggesting a feasible simpler alternative.

Gastroenterology news Specialties

Unraveling the Paradox: Why Smoking Benefits Ulcerative Colitis but Worsens Crohn’s Disease

By MedXY 09/04/2025

Recent research elucidates how smoking modulates gut microbiota and immune responses differently in ulcerative colitis and Crohn’s disease, explaining its protective effect in UC but detrimental role in CD.

Clinical Updates Gastroenterology Specialties

Afimkibart, an Anti-TL1A Antibody, in Moderately-to-Severely Active Ulcerative Colitis: Insights from the Phase 2b TUSCANY-2 Trial

By MedXY 08/26/2025

The TUSCANY-2 phase 2b trial evaluated afimkibart, a novel anti-TL1A antibody, in moderately-to-severely active ulcerative colitis, demonstrating favorable safety and clinically meaningful remission rates using modified Mayo scores despite primary endpoint statistical thresholds not being met by total Mayo scores.

Clinical Updates Gastroenterology news Specialties

Early Control of Ulcerative Colitis and Its Impact on Long-Term Outcomes: Insights from the UNIFI Phase 3 Study

By MedXY 08/26/2025

Achieving disease clearance early after induction therapy with ustekinumab in ulcerative colitis patients predicts sustained clinical remission, symptom control, and improved quality of life over four years.

$Cyclosporin Therapy: A Promising Rescue Treatment for Severe Steroid-Refractory Ulcerative Colitis$

Gastroenterology Specialties

Cyclosporin Therapy: A Promising Rescue Treatment for Severe Steroid-Refractory Ulcerative Colitis

By MedXY 08/17/2025

Cyclosporin demonstrated high clinical response rates in adults with severe steroid-refractory ulcerative colitis, allowing over half to avoid colectomy and highlighting its role as an effective rescue therapy.

Gastroenterology news Specialties

Durable Remission and Safety of Upadacitinib in Moderate to Severe Ulcerative Colitis: Insights from the Phase 3 U-ACTIVATE Long-Term Extension Interim Analysis

By MedXY 08/14/2025

Interim data from the U-ACTIVATE study demonstrate sustained clinical and endoscopic remission and a consistent safety profile for upadacitinib up to 3 years in moderate to severe ulcerative colitis.

Gastroenterology General Surgery news Specialties

Appendicectomy Plus Medical Therapy Significantly Reduces Relapse in Ulcerative Colitis: Insights from the ACCURE Trial

By MedXY 08/14/2025

The ACCURE trial demonstrates that laparoscopic appendicectomy combined with standard medical therapy significantly lowers 1-year relapse rates compared to medical therapy alone in ulcerative colitis patients in remission.

$Explainable Artificial Intelligence for Predicting Refractory Ulcerative Colitis: Insights from a Japanese Nationwide Registry$

AI Clinical Updates Gastroenterology news Specialties

Explainable Artificial Intelligence for Predicting Refractory Ulcerative Colitis: Insights from a Japanese Nationwide Registry

By MedXY 08/07/2025

A machine learning model using nationwide registry data accurately predicts long-term remission in refractory ulcerative colitis and identifies key prognostic factors such as pseudopolyps.

Clinical Updates Gastroenterology Specialties

Guselkumab for Crohn’s Disease and Ulcerative Colitis: Efficacy and Safety from Recent Phase 3 Trials

By MedXY 08/02/2025

Phase 3 studies demonstrate guselkumab's efficacy and safety as induction and maintenance therapy for moderate-to-severe Crohn's disease and ulcerative colitis, with superiority over placebo and favorable safety profiles.

Clinical Updates Gastroenterology news Specialties

Targeting TL1A in IBD: Safety and Efficacy of Tulisokibart in Crohn’s Disease and Ulcerative Colitis—Emerging Phase 2 Data

By MedXY 08/02/2025

Phase 2 trials show anti-TL1A antibody tulisokibart offers potential efficacy and good tolerability in refractory Crohn’s disease and ulcerative colitis, with ongoing phase 3 studies to confirm findings.